Based on randomized trials and on a meta-analysis of five trials involving more than 3000 AML patients, the association of GO with standard 3 + 7 induction was approved as a first-line treatment for adult patients diagnosed with CD33+ AML [54,55,56,57]. This evidence concerns the gene CD33 and acute myeloid leukemia.